"In 1976, 16 per cent of the value of the S&P 500 was intangibles, but today intangibles comprise almost 90 per cent of the S&P's total value." Financial Times

Ireland is a leading location for the development, exploitation and management of intellectual property ("IP"). According to IDA Ireland, the number of global companies centralising their IP management in Ireland has made Ireland one of the largest exporters of IP in the world. One of the key drivers for this is the attractive tax regime, including the 12.5% corporation tax rate on trading income, a 25% tax credit on the cost of eligible research and development activities, capital allowances on the cost of acquiring certain intangible assets and a large double tax treaty network to facilitate the flow of funds between Ireland and other countries.

Ireland is a member of the OECD and has been an active participant in the OECD BEPS project. Furthermore, following the recently announced OECD programme of work, commonly known as BEPS 2.0, Ireland's policy makers have committed to engaging with proposed revisions to the international tax framework for the "digital economy".

Ireland has signed double tax treaties with over 70 countries. The network of treaty partner countries is set out in the Appendix.

Facts and Figures

Ireland is home to eight of the top ten global technology companies, eight of the top ten global pharmaceutical companies and 15 of the top 25 medical devices firms in the world.

In recent years, Ireland has attracted a range of innovative social media companies, including Google, Facebook, Twitter and LinkedIn, all of whom have established their European headquarters here.

Corporation Tax - Rate of Tax

Ireland has two rates of corporation tax on income. The 12.5% rate applies to trading income of an Irish company. The 25% rate applies to non-trading, or passive income.

Generally, trading means the carrying on of business or the engaging in activities on a regular basis with a view to realising a profit.

The Irish Revenue Commissioners, in considering whether an activity constitutes the carrying on of a trade, look at whether there is commercial rationale for the type of situation proposed, whether there is real value added in Ireland and whether there are employees and/or directors in Ireland with sufficient levels of expertise and skill to actually carry on the trade.

Tax Deduction for Intangible Assets

Companies carrying on a trade in Ireland can claim a tax deduction on capital expenditure incurred on the acquisition or development of certain "specified intangible assets" for the purposes of their trade. Intangible assets include patents, registered designs, trademarks, certain know-how, domain names and goodwill directly attributable to those intangible assets.

The allowances can be offset against income generated from managing, developing or exploiting the intangible assets or income from selling goods or services that derived their value from the intangible assets. Allowances can be claimed where the intangible asset is acquired from another party (including an affiliate, where arm's length pricing rules apply).

Where the intangible asset is held for more than 5 years there is no clawback of the allowances on a disposal (unless the asset is sold to a connected company who wishes to claim allowances). This is an important measure as traditionally the risk of a future "recapture" of capital allowances can be problematic for companies with a high spend on capital.

There is also an exemption from Irish stamp duty on the transfer of specified intangible assets.

Research and Development (R&D) Tax Credits

R&D tax credits allow qualifying companies involved in the carrying on of R&D activities to benefit from a tax credit of 25% of R&D expenditure. The tax credit is in addition to the corporation tax deduction at 12.5% for qualifying expenditure.

The tax credit is used to reduce the company's corporation tax liability and any unused portion can be carried forward indefinitely. The amount of money that can be claimed back is limited to the greater of (i) the corporation tax paid by the company for the preceding ten accounting periods and (ii) the payroll liabilities for the period in which the expenditure on R&D activities was incurred. For a start-up company the limit will be the payroll taxes for the period in which the expenditure was incurred.

Tax credits are available to companies within the charge to Irish tax that undertake R&D activities within the European Economic Area. The relief is generally available for R&D activities carried out in areas such as software development, engineering, medical sciences, pharmaceuticals, agriculture and horticulture.

Payments of Patent Royalties

Payments of patent royalties by an Irish resident company are typically subject to withholding tax at 20%. Patent royalties paid to associated companies resident in another EU Member State, or paid in the course of a trade or business to a company resident in a country with which Ireland has a double tax treaty are generally exempt from withholding tax. The Revenue Commissioners issued a Statement of Practice in 2010 which effectively extends the relief from withholding tax on certain patent royalties paid to non-treaty countries. To avail of the exemption, certain conditions apply which include the fact that the royalty must be paid in respect of a foreign patent and the payment must be made in the course of the Irish paying company's trade. Prior approval of Irish Revenue will be required.

Knowledge Development Box

The Irish Finance Act 2015 introduced a 'knowledge development box' ("KDB"), which brought in an effective reduced rate of corporation tax of 6.25% for qualifying income derived from 'qualifying expenditure' in the EU by an Irish tax resident company. This relief applies to accounting periods which commence on or after 1 January 2018 and before 1 January 2021. A claim must be made within 12 months of the end of the relevant accounting period and should be made in the corporation tax return of the claimant company for the period.

The KDB was described, when introduced, as the first OECD-compliant KDB in the world, which means that it is in line with international guidelines, the OECD Action 5 Report published on 5 October 2015 and specifically the OECD's ‘Modified Nexus Approach’. Under the Modified Nexus Approach, only the expenditure incurred developing the intellectual property asset after it was acquired should qualify as qualifying expenditure.

Qualifying assets for the KDB include certain patented inventions and copyrighted software will be 'intellectual property' for the purposes of the definition of 'qualifying asset'. The definition also includes supplementary protection certificates for medicinal products, supplementary protection certificates for plant protection products and plant breeders’ rights. The intellectual property must be the result of R&D activities.

Qualifying income for the KDB constitutes income derived directly from the qualifying asset. A deduction of 50% of the qualifying profit from the specified trade will be allowable, resulting in an effective KDB tax rate of 6.25%. The greater amount of R&D that takes place by the Irish entity, the greater the proportion of income that may qualify for the KDB tax rate.

Qualifying expenditure on the qualifying assets, for the purposes of the KDB, means bona fide expenditure incurred by a company wholly and exclusively in the carrying on by it of R&D activities, where such activities lead to the development, improvement or creation of the "qualifying asset". Where expenditure on qualifying assets, carried out by a group company, will not be qualifying expenditure for these purposes, it may be deemed as uplift and qualify as 'uplift expenditure', up to 30% of the qualifying expenditure.

Maples Group

The Maples Group is a leading service provider offering clients a comprehensive range of legal services on the laws of the British Virgin Islands, the Cayman Islands, Ireland, Jersey and Luxembourg, and is an independent provider of fiduciary, fund services, regulatory and compliance, and entity formation and management services. The Maples Group distinguishes itself with a client-focused approach, providing solutions tailored to their specific needs. Its global network of lawyers and industry professionals are strategically located in the Americas, Europe, Asia and the Middle East to ensure that clients gain immediate access to expert advice and bespoke support, within convenient time zones. The Maples Group comprises over 1900 people worldwide, 400 of whom are based in our Dublin offices.

Further Information

If you require any further advice or assistance please speak to your usual Maples Group contact or the persons listed below.

CONTACTS

bioImage

Andrew Quinn

Partner

+353 1 619 2038

bioImage

William Fogarty

Partner

+353 1 619 2730

bioImage

Christine Fauroux

Associate

+353 1 619 2770

*
*
*
*

Please note that your email may be received and read by other Maples and Calder lawyers in addition to your intended recipient.

*
*
*

Please note that your email may be received and read by other Maples Group employees in addition to your intended recipient.

Connect

Want to get in touch ?

Contact Us